HUI Working Papers,
HUI Research

Abstract: The aim of this paper is to analyze the impact of the deregulation of the Norwegian pharmaceuticals market in 2001 on costs and availability of pharmaceutical products. Data has been collected from the annual reports of a sample of Norwegian pharmacies before and after the deregulation of the market. In addition, data regarding the number of pharmacies in each region in Norway has also been collected. In order to study costs, a translog function is estimated. Regressin models for the number of pharmacies in each region in Norway are also estimated. The results show that the costs of the individual pharmacies have not decreased as a consequence of the deregulation of the Norwegian pharmaceuticals market. The deregulation of the market did, however, increase the availability to pharmacy services substantially. The number of pharmacies increased from 392 in year 2000 to 524 in June 2004.

Keywords: Deregulation; pharmaceuticals; translog cost function

JEL-codes: I11; I18; L11

14 pages, April 4, 2007

Download statistics

Published as

Niklas Rudholm, (2008), 'Deregulating the Norwegian Pharmaceuticals Market - Consequences for Costs and Availability', Health Policy, vol 87, pages 258-263

• HUI Research
• Ordering Working Papers
• Home page for this series

Questions (including download problems) about the papers in this series should be directed to Hans Seerar Westerberg ()
Report other problems with accessing this service to Sune Karlsson ().

RePEc:hhs:huiwps:0007This page generated on 2024-09-13 22:15:09.